Scinai Immunotherapeutics
SCNI
12 hedge funds and large institutions have $213K invested in Scinai Immunotherapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
9% more funds holding
Funds holding: 11 → 12 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
23% less capital invested
Capital invested by funds: $277K → $213K (-$64.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$16.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.3K |
| 3 |
Millennium Management
New York
|
+$5.47K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$691 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$56.3K |
| 2 |
Morgan Stanley
New York
|
-$1.33K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$12 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $131K | +$16.8K | +3,248 | +15% |
|
|
AC
2
Armistice Capital
New York
| $63.2K | -$56.3K | -10,911 | -47% |
|
|
3
Citadel Advisors
Miami,
Florida
| $6.31K | +$6.3K | +1,221 | New |
|
|
4
Millennium Management
New York
| $5.48K | +$5.47K | +1,061 | New |
|
|
5
RhumbLine Advisers
Boston,
Massachusetts
| $3.44K | +$691 | +134 | +25% |
|
|
6
Morgan Stanley
New York
| $1.34K | -$1.33K | -258 | -50% |
|
7
UBS Group
Zurich,
Switzerland
| $1.1K | – | – | – |
|
8
Credit Agricole
Montrouge Cedex,
France
| $193 | – | – | – |
|
|
MSG
9
Main Street Group
Glen Allen,
Virginia
| $103 | – | – | – |
|
|
APC
10
Aspire Private Capital
Cornelius,
North Carolina
| $83 | – | – | – |
|
|
GRP
11
Global Retirement Partners
San Rafael,
California
| $26 | – | – | – |
|
12
Qube Research & Technologies (QRT)
London,
United Kingdom
| $4 | – | – | – |
|
|
13
Wells Fargo
San Francisco,
California
| – | -$12 | -2 | Closed |
|
SCNI Hedge Fund Activity: Q1 2024 in Review
12 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2024, worth a combined $213K — down 23% from $277K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SCNI positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, adding an estimated $16.8K. The largest seller was Armistice Capital, cutting an estimated $56.3K.
- 12 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2024, up from 11 in Q4 2023.
- Funds reported $213K of Scinai Immunotherapeutics stock for Q1 2024, down 23% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q1 2024 and 1 closed out, a net change of +1 holder.
- The largest Scinai Immunotherapeutics buyer in Q1 2024 was Sabby Management, an estimated $16.8K added.
- The largest Scinai Immunotherapeutics seller in Q1 2024 was Armistice Capital, an estimated $56.3K sold.
Based on aggregated 13F filings for Q1 2024.